Mark Ragosa Kiniksa Pharmaceuticals, Ltd. (KNSA) insider trading activity

Mark Ragosa is CHIEF FINANCIAL OFFICER of Kiniksa Pharmaceuticals, Ltd.. Currently has a direct ownership of 27,009 shares of KNSA, which is worth approximately $753,010. The most recent transaction as insider was on Sep 01, 2023, when has been sold 791 shares (Class A Common Share) at a price of $17.76 per share, resulting in proceeds of $14,048. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 27K

1.93% 3M change

40.28% 12M change

Total Value Held $753,010

Mark Ragosa Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 01 2023	SELL Payment of exercise price or tax liability	$14,048 $17.76 p/Share	791 Reduced 5.24%	14,318 Class A Common Share
Sep 01 2023	BUY Exercise of conversion of derivative security	-	2,695 Added 15.14%	15,109 Class A Common Share
Apr 26 2023	SELL Payment of exercise price or tax liability	$3,244 $11.15 p/Share	291 Reduced 2.29%	12,414 Class A Common Share
Apr 26 2023	BUY Exercise of conversion of derivative security	-	990 Added 7.23%	12,705 Class A Common Share
Apr 10 2023	SELL Payment of exercise price or tax liability	$8,471 $10.71 p/Share	791 Reduced 6.32%	11,715 Class A Common Share
Apr 10 2023	BUY Exercise of conversion of derivative security	-	2,695 Added 17.73%	12,506 Class A Common Share
Mar 20 2023	SELL Payment of exercise price or tax liability	$7,050 $11.12 p/Share	634 Reduced 6.07%	9,811 Class A Common Share
Mar 20 2023	BUY Exercise of conversion of derivative security	-	2,158 Added 17.12%	10,445 Class A Common Share
Mar 16 2023	SELL Payment of exercise price or tax liability	$2,933 $11.46 p/Share	256 Reduced 3.0%	8,287 Class A Common Share
Mar 16 2023	BUY Exercise of conversion of derivative security	-	872 Added 9.26%	8,543 Class A Common Share
Sep 02 2022	SELL Payment of exercise price or tax liability	$6,258 $11.44 p/Share	547 Reduced 6.66%	7,671 Class A Common Share
Sep 02 2022	BUY Exercise of conversion of derivative security	-	1,861 Added 18.46%	8,218 Class A Common Share
Apr 26 2022	SELL Payment of exercise price or tax liability	$2,817 $9.99 p/Share	282 Reduced 4.25%	6,357 Class A Common Share
Apr 26 2022	BUY Exercise of conversion of derivative security	-	991 Added 12.99%	6,639 Class A Common Share
Mar 21 2022	SELL Payment of exercise price or tax liability	$11,496 $10.98 p/Share	1,047 Reduced 15.64%	5,648 Class A Common Share
Mar 21 2022	BUY Exercise of conversion of derivative security	-	3,019 Added 31.08%	6,695 Class A Common Share
Mar 16 2022	SELL Payment of exercise price or tax liability	$3,069 $10.13 p/Share	303 Reduced 7.61%	3,676 Class A Common Share
Mar 16 2022	BUY Exercise of conversion of derivative security	-	872 Added 17.98%	3,979 Class A Common Share
Dec 31 2020	SELL Payment of exercise price or tax liability	$22,918 $17.67 p/Share	1,297 Reduced 29.45%	3,107 Class A Common Share
Dec 31 2020	BUY Exercise of conversion of derivative security	-	4,404 Added 50.0%	4,404 Class A Common Share

Mark Ragosa

CHIEF FINANCIAL OFFICER

Hamilton, D0

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNSA shares.

Notify only if

Value

Insider Trading

Get notified when an Kiniksa Pharmaceuticals, Ltd. insider buys or sells KNSA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kiniksa Pharmaceuticals, Ltd.

Track Activities on KNSA

Account